MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

Phase 2agenT-797Positive

AI Analysis

Summary

MiNK Therapeutics presented initial observations from its ongoing Phase 2 trial of agenT-797 in patients with severe hypoxemic pneumonia at the 2026 Military Health System Research Symposium. The company is developing off-the-shelf allogeneic invariant natural killer T-cell therapies for cancer and immune disorders.

Clinical Trial Data

Phase

Phase 2

Outcome Details

initial observations from patients presented at 2026 Military Health System Research Symposium

Importance:5/10

Sentiment:

0.40

Phase 2iNKT cell therapyallogeneicsevere hypoxemic pneumoniadata presentation

Related Companies

$INKT

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 4:00 PM

Read Original